Breaking Finance News

A statement released earlier today by Zacks Investment Research about Mast Therapeutics Inc (NASDAQ:MSTX) bumps the target price to $0.25

Yesterday Mast Therapeutics Inc (NASDAQ:MSTX) traded -4.28% lower at $0.13. The company’s 50-day moving average is $0.44 and its 200-day moving average is $0.37. The last closing price is down -65.95% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 23,151,235 shares of the stock were exchanged, up from an average trading volume of 7,334,930

Mast Therapeutics Inc (NASDAQ:MSTX) had its target price raised to $0.25 by Zacks Investment Research in a report released 9/23/2016. The new target price indicates a possible upside of 0.92% based on the company's last closing price.

See Chart Below

Mast Therapeutics Inc (NASDAQ:MSTX)

Mast Therapeutics Inc has a 52 week low of $0.10 and a 52 week high of $0.71 The company’s market cap is currently $0.

General Information About Mast Therapeutics Inc (NASDAQ:MSTX)

Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.